Sanofi: Invest Securities adjusts target price
(CercleFinance.com) - Invest Securities has reinstated its "buy" rating on the Sanofi share, while trimming its target price from 87 euros to 85 euros, after adjusting its 2018-20 EPS estimates by -1%, -5.
7% and -5% in 2020.
The second quarter should be delicate for the group again, with Sanofi still impacted by the Diabetes franchise and MS, an ongoing storage effect of Dupixent and a difficult comparison basis for the Vaccines franchise, warns the analyst who monitors the stock.
However, he said that he remains more optimistic about the second half of the year with the integration of Bioverativ and Ablynx, the group's share buyback program, improvements at Dupixent and Praluent and the approval of Sotagliflozin.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
7% and -5% in 2020.
The second quarter should be delicate for the group again, with Sanofi still impacted by the Diabetes franchise and MS, an ongoing storage effect of Dupixent and a difficult comparison basis for the Vaccines franchise, warns the analyst who monitors the stock.
However, he said that he remains more optimistic about the second half of the year with the integration of Bioverativ and Ablynx, the group's share buyback program, improvements at Dupixent and Praluent and the approval of Sotagliflozin.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.